Zealand Pharma A/S
Zealand announces total number of shares and voting rights in the company as of 30 June 2015

Zealand Pharma A/S 

30.06.2015 13:23

Dissemination of a Adhoc News, transmitted by DGAP - a service of EQS Group
AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Copenhagen, 2015-06-30 13:23 CEST (GLOBE NEWSWIRE) -- Copenhagen, 30 June 2015
- In accordance with Section 6 of the Danish Statutory Order on Issuers'
Disclosure Obligations, Zealand announces the total share capital and number of
voting rights in the company at the end of a calendar month in which changes to
the equity capital have occurred. 

With reference to Corporate Announcement no. 24/2015 dated 2 June 2015 and
28/2015 dated 20 June 2015, the table below provides the total number of shares
and voting rights in Zealand as of 30 June 2015. 



             Number of shares  Nominal value  Number of votes
        (nominal value DKK 1)          (DKK)                 
-------------------------------------------------------------
Shares             23,518,108     23,518,108       23,518,108
-------------------------------------------------------------

                                        

                                      ●●●●●

For further information, please contact:
Hanne Leth Hillman, Senior Vice President for Investor Relations and
Communications 
Tel: +45 50 60 36 89, email: hlh@zealandpharma.com



About Zealand Pharma
Zealand Pharma A/S ('Zealand') (Nasdaq Copenhagen: ZEAL) is a biotechnology
company based in Copenhagen, Denmark. Zealand has leading expertise in the
discovery, design and development of novel peptide medicines and possesses
in-house competences in clinical trial design and management with a therapeutic
focus on metabolic diseases and acute care indications. The company is
advancing a proprietary pipeline of novel medicines alongside a partnered
product and development portfolio. 

Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1
agonist for the treatment of Type 2 diabetes, is marketed globally (ex-US) as
Lyxumia(R) and is in Phase III development as a single-injection combination with
Lantus(R) (LixiLan), both under a global license agreement with Sanofi. US
regulatory filing for Lyxumia(R) is planned for Q3 2015 and filing for LixiLan is
planned for Q4 2015 in the US and Q1 2016 in Europe. 

Zealand's proprietary pipeline include danegaptide (prevention of Ischemic
Reperfusion Injury) in Phase II and the stable glucagon analogue, ZP4207 in two
Phase I trials as a single-use rescue pen (severe hypoglycemia) and a
multiple-dose version (mild to moderate hypoglycemia) as well as several
preclinical peptide therapeutics. Partnering represents an important component
of the strategy to leverage in-house expertise, share development risk in large
clinical trials, provide funding and commercialize the company's products.
Zealand currently has global license agreements and partnerships with Sanofi,
Helsinn Healthcare and Boehringer Ingelheim. 


For further information: www.zealandpharma.com     Follow us on Twitter
@ZealandPharma
News Source: NASDAQ OMX



30.06.2015 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Zealand Pharma A/S
              
               
              Denmark
Phone:        
Fax:          
E-mail:       
Internet:     
ISIN:         DK0060257814
WKN:          
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------